What is the main business of Novo Nordisk Pharma?

The main business activity of Novo Nordisk Pharma focuses on research and experimental development in natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 18, 2002.

Where is the headquarters located?

The headquarters is located at: ul. Krakowiaków 46, 02-255 Warszawa.

What is the share capital?

The share capital of the company is PLN 9,021,000 (approx. $2.4 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of USD 126,524,177 in 2025, which is an increase of 20.9% compared to 2024.

Yes, in 2025 the company was profitable, achieving a net profit of USD 7,855,414, meaning the company decreased its profit by 34.0%.

What is the largest operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to USD 45,647,944 in 2025, representing 39% of all operating expenses.

Novo Nordisk Pharmasp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2002-02-18

Share capital

9 021 000,00 PLN

Activity description

Novo Nordisk Pharma Sp. z o.o. is the Polish entity of the global healthcare company Novo Nordisk, founded in Denmark in 1923. The company develops therapies for people with diabetes and other serious chronic diseases.

Registered address

ul. Krakowiaków 46, 02-255 Warszawa, Poland

Website

novonordisk.pl

Phone

Social media

Electronic delivery address

AE:PL-15139-73037-GVBCC-33

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 126.52mMedianUSD 133.91kAverageUSD 4.65m

Net profit

This companyUSD 7.86mMedianUSD -54.78AverageUSD 310.10k

Operating costs

This companyUSD 118.29mMedianUSD 175.72kAverageUSD 4.46m

Assets

This companyUSD 64.81mMedianUSD 254.44kAverageUSD 8.12m

Industry

Bank accounts

Registered as a VAT taxpayer on 1996-07-01. Active

ING Bank Śląski
73 1050 0086 1000 0090 3050 2950

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

Type	Amount
Buildings and premises	PLN 1.1MPLN 1,088,170

MSiG notices

Publication date	Event
Oct 3, 2014	Call to creditors

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Trademarks

Novo Nordisk Pharma currently holds no active trademarks with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2001.

Mark	Number	Classes	Status	Protected until
i NovoSerwis	Z.246094	1, 2, 4, 5, 35, 36, 39, 42, 44	Not registered	–
@ NovoWebCafe	Z.246095	1, 2, 4, 5, 35, 36, 39, 42, 44	Not registered	–
@ novowebcafe	Z.240113	0, 44	Expired	–
i novoserwis	Z.240112	0, 44	Expired	–

Mark	Protected until
i NovoSerwis	–
@ NovoWebCafe	–
@ novowebcafe	–
i novoserwis	–

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Cédric Jean-Paul Molla – Management Board Member

Sławomir Dominik Stachowicz – Attorney-in-fact (sole)

Jose Garcia Eboli – Management Board Member

Magdalena Edyta Paradzińska – Attorney-in-fact (sole)

Katarzyna Magdalena Kacperska – Management Board Member

Manner of representation

Each member of the management board is authorised to represent the company independently.

Ownership

Owner	Shares	Share value	Stake
Novo Nordisk Region Europe A/s	58,041	$135.06	0.0055%
Others	1,047,117,681	$2,436,655.86	99.9945%

Beneficial owners

Person	Rights

Competitors

	Name	Revenue	Website
	Polpharma BiologicsS.A.	$311,661,837.06	polpharmabiologics.com

Change history

Date	Event
2018-11-16	Address change (Ul. Komitetu Obrony Robotników 45b, 02-146, Warszawa → Ul. Krakowiaków 46, 02-255, Warszawa)
2018-02-07	Address change (17 Stycznia 45 B, 02-146, Warszawa → Ul. Komitetu Obrony Robotników 45b, 02-146, Warszawa)
2015-02-13	Share capital change (29,021,000.00 PLN → 9,021,000.00 PLN)
2008-12-18	Address change (17 Stycznia 45 B, 01-002, Warszawa → 17 Stycznia 45 B, 02-146, Warszawa)
2008-12-01	Address change (Mineralna 15, 02-274, Warszawa → 17 Stycznia 45 B, 01-002, Warszawa)

FAQ

Last updated: 2026-10-07